Intelligent, Multimodal Agentic Solutions to Reimagine Pharma Patient Services.

Intelligent, Multimodal
Agentic Solutions to
Reimagine Pharma
Patient Services.

High-Value Solutions Defining the
Future of Patient Support Programs

A single Phluence solution leverages true agentic AI — it brings together the right AI agents and the right patient insights at the right time for true, orchestrated multiagent system collaboration to execute highly complex workflows critical to modern pharma patient support services.

Patient Engagement Solutions

  • Patient Marketing Agent
  • Enrollment Agent
  • Call Center/Contact Center Agent
  • Consented Patient Pipeline

Intelligent Workflow


  • Patient Case Management Agent
  • FRM Automation Agent
  • HCP Workflow Agent
  • Market Access Insight Agent

Revenue Conversion Solutions

  • Bridge Conversion Agent
  • Benefit Sentinel
  • Gross-to-Net (GTN) Optimization Agent

An Architecture to Build an Advanced Patient Support Platform.

Given the complex reimbursement and access landscape, pharmaceutical companies have no choice but to reimagine their Patient Support programs. Traditional hub models are expensive to operate and often struggle to help patients reliably get on — and stay on — their medicines. Phluence provides an architecture to reinvent pharma patient services. With the Phluence Platform and an operating system designed to serve the needs of market access stakeholders, our system excels at building solutions that manage complex workflows 24 hours a day, 7 days a week, without increasing the human footprint of a manufacturer’s patient services operation.

Dynamic

A well-assembled multiagent system allows patient support programs to dynamically reconfigure workflows, resources, and engagement strategies based on performance signals. Agents can
coordinate across functions — financial assistance, clinical education, and case management — to optimize outcomes holistically rather than in silos. This creates a system that not only executes tasks but actively manages and improves itself. In doing so, manufacturers gain a future-proof foundation capable of scaling with innovation, complexity, and growing patient expectations.

Responsive

AI-driven agents can orchestrate real-time responses to patient and provider needs, reducing delays in access, onboarding, and ongoing support. Whether handling benefit verification, prior authorization follow-ups, or patient inquiries, agents can act instantly while escalating complex cases to human specialists when needed. This responsiveness improves patient experience and adherence by minimizing friction at critical moments in the treatment journey. For manufacturers, it translates into faster therapy starts and more consistent engagement.

Adaptive

A multiagent system enables patient support programs to continuously learn from real- world interactions, tailoring services to evolving patient needs, therapy changes, and regulatory environments. By integrating data across channels — hub services, adherence tools, and patient feedback — AI agents can personalize outreach, education, and interventions at scale. This adaptability allows manufacturers to move beyond static program designs toward living systems that improve outcomes over time. Ultimately, it ensures support programs remain relevant as therapies,

How can the Phluence™ multiagent system help you?

Phluence builds custom agentic solutions to address the unique needs of your pharma patient support services program. Contact us today to learn more.

*Required fields

Please read our Privacy Policy to see how we use your personal information.

News & Insights

What AFPs Are, How They Evolved, and Why They Matter Now

Part 1 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue & Patient Care Alternate Funding Programs have evolved into a powerful but largely invisible force in specialty pharma—reshaping patient access, distorting brand

Recent Articles

Part 1 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue &...

April 23, 2026

Part 2 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue &...

April 23, 2026

Part 3 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue &...

April 23, 2026

The Emerging Prerequisite to Drug Affordability: Digital Patient Engagement Drug affordability is one of the...

April 21, 2026